Zealand Pharma

Zealand Pharma has over two decades of expertise in peptide drug discovery. The company has successfully brought several products to market through partnerships—most notably lixisenatide and Soliqua with Sanofi for T2DM, as well as Zegalogue® for severe hypoglycemia. Its pipeline spans obesity, rare diseases like congenital hyperinsulinism and short bowel syndrome, MASH/NASH, type I diabetes, and more. Recent years have seen significant clinical progress in obesity assets—including a Phase III program with Boehringer Ingelheim—and regulatory submissions for rare disease treatments. The company raised substantial capital (~$1.2B USD) in late-stage financings to support its next growth phase.